secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-107874
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M
--------------------------------------------------------------------------------

- Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.
- Cash $50.9M at Sep 30; completed $30M stock/warrant offering extending runway into H1 2026.
- BEACON investigation: no drug substance or product issues; focus now on clinical site processes.
- Final BEACON conclusions expected Q4 2025; additional data from BEACON and OLE in H1 Q1 2026 for Phase 2b dose selection.
- Initial data from ETESIAN asthma study planned for Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/0001213900-25-107874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025107874/ea0264586-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer